Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Share-based Compensation (2020 - 2025)

Foghorn Therapeutics has reported Share-based Compensation over the past 6 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $2.2 million for Q4 2025, down 9.75% from a year ago — trailing twelve months through Dec 2025 was $10.4 million (down 12.56% YoY), and the annual figure for FY2025 was $10.4 million, down 12.56%.
  • Share-based Compensation for Q4 2025 was $2.2 million at Foghorn Therapeutics, down from $2.7 million in the prior quarter.
  • Over the last five years, Share-based Compensation for FHTX hit a ceiling of $4.6 million in Q1 2023 and a floor of $1.9 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $3.0 million (2023), compared with a mean of $3.1 million.
  • Biggest five-year swings in Share-based Compensation: surged 317.59% in 2021 and later decreased 29.48% in 2024.
  • Foghorn Therapeutics' Share-based Compensation stood at $2.1 million in 2021, then surged by 81.43% to $3.8 million in 2022, then fell by 19.31% to $3.1 million in 2023, then fell by 18.62% to $2.5 million in 2024, then fell by 9.75% to $2.2 million in 2025.
  • The last three reported values for Share-based Compensation were $2.2 million (Q4 2025), $2.7 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.